Quince Therapeutics, Inc. (QNCX) Stock Analysis & Investment Frameworks
Quince Therapeutics, Inc. (QNCX) stock analysis on Invetso. Review Quince Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Quince Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Quince Therapeutics, Inc. Key Financial Metrics
- Market Cap: $8.83M
- Revenue: $N/A
- ROE: -413.28%
- ROIC: -104.64%
- Dividend Yield: N/A
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Quince Therapeutics, Inc. Investment Frameworks
Invetso analyzes Quince Therapeutics, Inc. (QNCX) across the following frameworks:
- Quince Therapeutics, Inc. 10Y Growth Potential
- Quince Therapeutics, Inc. Scenario Analysis
- Quince Therapeutics, Inc. Risks & Opportunities
- Quince Therapeutics, Inc. Economic Moat
- Quince Therapeutics, Inc. Business Model
- Quince Therapeutics, Inc. Management
- Quince Therapeutics, Inc. SWOT Analysis
- Quince Therapeutics, Inc. Porter's 5 Forces
- Quince Therapeutics, Inc. PESTLE Analysis
- Quince Therapeutics, Inc. ESG Analysis